Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range

Journal of Pharmacological Sciences
Satoko BabaMichiko Ono


Antagonism of the dopamine D3 receptor has been hypothesized to be beneficial for schizophrenia cognitive deficits, negative symptoms and extrapyramidal symptoms. However, recent animal and human studies have shown that most antipsychotics do not occupy D3 receptors in vivo, despite their considerable binding affinity for this receptor in vitro. In the present study, we investigated the D3 receptor binding of blonanserin, a dopamine D2/D3 and serotonin 5-HT2A receptors antagonist, in vitro and in vivo. Blonanserin showed the most potent binding affinity for human D3 receptors among the tested atypical antipsychotics (risperidone, olanzapine and aripiprazole). Our GTPγS-binding assay demonstrated that blonanserin acts as a potent full antagonist for human D3 receptors. All test-drugs exhibited antipsychotic-like efficacy in methamphetamine-induced hyperactivity in rats. Treatment with blonanserin at its effective dose blocked the binding of [(3)H]-(+)-PHNO, a D2/D3 receptor radiotracer, both in the D2 receptor-rich region (striatum) and the D3 receptor-rich region (cerebellum lobes 9 and 10). On the other hand, the occupancies of other test-drugs for D3 receptors were relatively low. In conclusion, we have shown that blonanserin...Continue Reading


Sep 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D LévesqueP Sokoloff
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Apr 23, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Patrick N McCormickAlan A Wilson
May 13, 2010·Pharmacology, Biochemistry, and Behavior·Yukihiro OhnoSaki Shimizu
Dec 24, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ragy R GirgisMark Slifstein
Jan 27, 2012·Human Psychopharmacology·Tomomi TenjinNoboru Yamaguchi
Nov 7, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Gerhard GrossKarla U Drescher
Jan 19, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Patrick N McCormickGary J Remington
Jun 25, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Shinichiro NakajimaAriel Graff-Guerrero
Dec 26, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Saki ShimizuYukihiro Ohno


Jun 28, 2016·Pharmacology & Therapeutics·Gian Marco LeggioFilippo Drago
Sep 13, 2019·The Journal of Pharmacology and Experimental Therapeutics·Mei HuangH Y Meltzer
Dec 5, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Maria Serena PaladiniRaffaella Molteni

Related Concepts

Dose-Response Relationship, Drug
Hyperkinesia, Generalized
Plasma Protein Binding Capacity
Antipsychotic Effect

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.


This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here